Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.

Experimental neurology - 1 May 2015

Smith Rosamund C, O'Bryan Linda M, Mitchell Pamela J, Leung Donmienne, Ghanem Mahmoud, Wilson Jonathan M, Hanson Jeff C, Sossick Sandra, Cooper Jane, Huang Lihua, Merchant Kalpana M, Lu Jirong, O'Neill Michael J

Abstract excerpt

Several lines of evidence indicate that Glial cell line-derived neurotrophic factor (GDNF) is a trophic factor for dopaminergic neurons. Direct parenchymal administration of GDNF is robustly neuroprotective and neurorestorative in multiple neurotoxin-based animal models (rat and non-human primate (NHP)) of Parkinson's Disease (PD), suggesting its potential as a therapeutic agent. Although small, open-label...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibrinolytic Agents
Share to Glial Cell Line-Derived Neurotrophic Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heparin

Share to Immunogenetic Phenomena

Share to Neurites

Share to Oxidopamine

Share to PC12 Cells

Share to Rats, Sprague-Dawley

Source

Identifiers

PMID: 25771799
DOI: 10.1016/j.expneurol.2015.03.002

Genes

GDNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.PMID 25771799Read ↗

Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.Semantic proximity Read ↗

Using Extracellular Vesicles Released by GDNF-transfected Macrophages for Therapy of Parkinson’s DiseaseSemantic proximity Read ↗

Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative DiseasesSemantic proximity Read ↗

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disordersSemantic proximity Read ↗

Production of highly pure human glycosylated GDNF in a mammalian cell line.Semantic proximity Read ↗

Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo.Semantic proximity Read ↗

Cracking the Blood–Brain Barrier Code: Rational Nanomaterial Design for Next-Generation Neurological TherapiesSemantic proximity Read ↗

NN-800s: Brain-penetrant trimeric nanobodies enable potent TNFα inhibition via TfR1-mediated transcytosisSemantic proximity Read ↗

Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington’s diseaseSemantic proximity Read ↗

Striatal GDNF System Elicits Chemoattraction to RET Positive Dopamine Axons Seven Times Longer in Distance than the Abundant Medium Spiny Neurons and Covers Approximately One Twelfth of the Striatal Neuronal VolumeSemantic proximity Read ↗

Novel VHH targeting a unique TfR1 epitope for efficient cross-species delivery of drugs in the CNSSemantic proximity Read ↗

Construction and preliminary characterization of human recombinant proNGF-A variant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.